Replies to post #94281 on Biotech Values

[its_the_oxygen]

Turtle, that is exactly what I'm hoping. I'm more than sure managemnet will do what they can to avoid a dilutive event but if we do raise money, IMHO, this will subsequently raise the partnership price tag because of the cost of delay and the extra life time they will have on their own. If these data continue to look like yesterday's data then we all may be better suited sticking through a financing and waiting until things mature a bit more. Just a thought.

[gym gravity]

If a milestone triggers, the pr should be good for a stock price that would allow financing at a much less dilutive price though.

They could play patient and cool though and hold out for a big HCV partner.

In Dew's recent conversation of valuation I wanted to ask what he thought of IDIX near $10 in 2008.

They probably had a little more cash at that time than they do now, pre-GSK partnership, and pipeline was much earlier in development.

My point would be that Those Who Bought it up to $10 should be at least as interested in taking it to double digits again.

[DewDiligence]

When the first patient is dosed on IDX899, IDIX should receive about a quarter’s worth of cash, right?

My estimate is $10M—see #msg-45620605. The actual amounts of the IDX899 milestone payments will not be disclosed, although investors will be able to approximate these amounts ex post facto by scrutinizing the quarterly P&L statements.